Pediatric Trazodone Liquid Formulation for Stable Low-Dose Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of controlled clinical trials evaluating the efficacy and safety of trazodone for pediatric insomnia, and existing liquid compositions are not suitable for pediatric use due to unclear metabolic pathways, instability, bitter taste, and use of excipients that may cause adverse effects.
Innovation Solution
Development of low-dose trazodone pediatric formulations in palatable syrups and drops, using pediatric-friendly excipients like PEG 400 and glycerol, with concentrations ranging from 0.1% to 4% w/V, stable at pH 4.5 to 5.5, and suitable for administration with food or drinks, avoiding ethanol and other harmful solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If existing liquid trazodone compositions (6% w/V or 1% w/V) are used for pediatric administration, then the drug can be administered in liquid form, but the compositions are unstable, have bitter taste, and contain excipients that may cause adverse effects in children
Solution Approach 1:
The patent changes the concentration parameter from high (6% w/V) to low (0.1-4% w/V) trazodone concentrations suitable for pediatric use. It also modifies the pH parameter to 4.5-5.5 range and changes the solvent system from ethanol-containing to PEG 400 and glycerol-based, resolving the stability and safety issues while maintaining liquid administration form
Solution Approach 2:
The patent introduces PEG 400 and glycerol as intermediary solvents that replace harmful ethanol and enable stable low-concentration trazodone formulations. These intermediaries provide both solubility for the drug and safety for pediatric administration, eliminating the adverse effects associated with traditional excipients
2Quantity of substance
If high concentration trazodone compositions (6% w/V) are used, then the dosage volume is small, but the compositions are not suitable for pediatric use due to instability and adverse effects from excipients
Solution Approach 1:
The patent uses PEG 400 and glycerol as safe intermediary solvents that replace harmful excipients like ethanol. These intermediaries enable the use of lower trazodone concentrations (0.1-4% w/V) while eliminating adverse effects, making the composition suitable for pediatric administration
Solution Approach 2:
The patent changes the concentration parameter from high (6% w/V) to low (0.1-4% w/V) trazodone concentrations suitable for pediatric use, and modifies the solvent composition parameter to eliminate harmful excipients while maintaining stability and safety
3Reliability
If trazodone is administered to pediatric population, then insomnia treatment is provided, but there is a lack of controlled clinical trials and unclear metabolic pathways in children
Solution Approach 1:
The patent performs preliminary pharmacokinetic studies in pediatric population before widespread clinical use. It establishes age-stratified dosing regimens (2-5 years: 0.2-0.4 mg/kg; 6-12 years: 0.4-0.6 mg/kg; 13-17 years: 0.6-1.2 mg/kg) and characterizes metabolic pathways involving CYP3A4, CYP3A5, CYP2C19, and CYP2D6 enzymes, providing a foundation for safe and effective treatment
4Object-affected harmful factors
If low dose trazodone is used for pediatric insomnia, then adverse effects are reduced, but the formulations must be highly stable and palatable to ensure compliance
Solution Approach 1:
The patent optimizes the pH parameter to 4.5-5.5 range and uses PEG 400 and glycerol as co-solvents to improve palatability and stability. These parameter changes ensure the low-dose formulation (0.1-4% w/V) remains stable and acceptable to pediatric patients, maintaining compliance while reducing adverse effects
Solution Approach 2:
The patent introduces PEG 400 and glycerol as intermediary substances that improve the sensory properties and stability of low-dose trazodone formulations. These intermediaries enhance palatability and ensure formulation stability, making the medication more acceptable to children while maintaining the low-dose safety profile
Data Source
AI summary
The invention relates to trazodone for use in the treatment of insomnia in the pediatric population, wherein said pediatric population is affected by an Intellectual Disability or a Neurodevelopmental Disorder. The invention also relates to pediatric formulations at a trazodone concentration comprised of from 0.1 to 4% and pediatrically suitable excipients.